EURECA · EURopean Epitranscriptomics of Cancer Academy
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2025-11-01 → 2029-10-31
- Финансиране от ЕС
- 4 157 935 €
- Участници
- 19
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите.
Накратко на български
Епитранскриптомът изследва модификации на РНК, като например метилирането, които регулират работата на гените. Разбирането на тези процеси при различни видове рак помага за търсенето на нови биомаркери и по-добри стратегии за диагностика и терапия.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
The overarching objective of EURECA - The European Epitranscriptomics of Cancer Academy, is to train young doctoral candidatesinto excellence at the frontiers of basic and translational research by exploiting the cancer epitranscriptome to answer unmet clinicalneeds in cancer diagnosis, prognosis, and therapeutics and to drive change through knowledge and research.Epitranscriptomics is a new science field that studies RNA modifications (epitranscriptomic marks) and their function in regulation ofgene expression. It is long known that many different RNA modifications exist. Yet, the true dimensions of the epitranscriptome wereunveiled only in the last decade. It is now evident that RNA modifications affect the stability, function, subcellular localization andeven immunogenicity of RNA to modulate essential cell programs like cell proliferation, differentiation, and stress response.Pathological changes in the epitranscriptome are seen as a new cancer hallmark: an independent mode of genetic reprogrammingshaping cancer’s cell fate. We thus foresee that the epitranscriptome will prove to be a fundamental layer of gene regulationamenable to the clinics as a valuable tool in cancer diagnosis, prognosis and therapy.Focusing on RNA methylation and RNA editing in three different cancers, EURECA’s doctoral candidates will investigate thecommonalities and differences in the epitranscriptomic landscape and underlying mechanisms, while searching for novel biomarkersand treatment strategies to combat cancer and while expanding the epitranscriptomics toolbox. The candidates will join a purposelyestablished European network of outstanding academic groups and innovative biotech companies devoted to advancing thefundamental knowledge of RNA modifications and its translation to innovative solutions for patient care. The EURECA DoctoralNetwork is the first European effort to challenge the uncharted territory of the epitranscriptome for the benefit of cancer patients.
Оригинален текст от CORDIS (на английски).
Участници
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM · RotterdamКоординаторНидерландия
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisФранция
- FLOMICS BIOTECH SL · BARCELONAИспания
- FUNDACIO CENTRE DE REGULACIO GENOMICA · BarcelonaИспания
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisФранция
- INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE · PortoПортугалия
- JOHANNES GUTENBERG-UNIVERSITAT MAINZ · MainzГермания
- Lexogen GmbH · WienАвстрия
- MEDIZINISCHE UNIVERSITAET WIEN · WienАвстрия
- OPEN SCIENCE - LEBENSWISSENSCHAFTEN IM DIALOG · WienАвстрия
- STICHTING EUROPEAN UROLOGICAL FOUNDATION · ArnhemНидерландия
- UNIVERSIDAD POMPEU FABRA · BarcelonaИспания
- UNIVERSIDADE DO PORTO · PortoПортугалия
- UNIVERSITA DEGLI STUDI DI BARI ALDO MORO · BariИталия
- UNIVERSITA DEGLI STUDI DI TRENTO · TrentoИталия
- UNIVERSITE DE LORRAINE · Nancy CedexФранция
- UNIVERSITE DE MONTPELLIER · MontpellierФранция
- UNIVERSITE LIBRE DE BRUXELLES · Bruxelles / BrusselБелгия
- UNIVERSITE LYON 1 CLAUDE BERNARD · Villeurbanne CedexФранция
Връзки
Данни: CORDIS, © Европейски съюз